l carnitine and tmao Characterization of productivity from challenge facilitates personalized nutrition microbiome signatures discovery | Microbiome Optimal DX FYI: Gut Microbes

Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions

What FDA-approved treatments or non-drug options are available, and why might they be preferred

: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH : C35H48N10O15 : 848,81 : 99,4% DSIP ,

In order to maintain consistency with the rest of our study, we did not attempt to alter neural activation prior to euthanizing mice in the cAMP detection experiment